leadf
logo-loader
LSE:TILS NASDAQ:TLSA

Tiziana Life Sciences PLC

Receive alerts
Market:
LSE
Market Cap:
£203.37 m
Price
104.50 GBX
Change
-2.34%
52 weeks high
300.00
52 weeks low
27.50

In brief

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, LSE:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma. Tiziana is led by a team of highly qualified executives with extensive drug development and commercialization experience.

Snapshot

  • US and UK listed biotech with three key monoclonal antibody treatments
  • Has applied for a patent for possible coronavirus treatment
  • Other products target liver cancer and autoimmune diseases